Pelossof Avi

SEC source: 0000711377-26-000025 · primary_doc.xml · derivative · entry 2

Pelossof Avi · CIK 0001293460 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,558

Underlying: Common Stock · 20,558 shares

Expires 2036-10-01

F1 · derivative.exercise_date: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants

SEC source: 0000711377-26-000025 · primary_doc.xml · nonDerivative · entry 1

Pelossof Avi · CIK 0001293460 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,804

F1 · shares: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants

SEC source: 0000711377-25-000058 · primary_doc.xml · derivative · entry 2

Pelossof Avi · CIK 0001293460 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,929

Underlying: Common Stock · 49,929 shares

Expires 2035-10-24

F1 · derivative.exercise_date: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants

SEC source: 0000711377-25-000058 · primary_doc.xml · nonDerivative · entry 1

Pelossof Avi · CIK 0001293460 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,386

F1 · shares: Options and RSUs vest in equal annual installments on each of the first three anniversary dates of the grants

SEC source: 0000950142-17-001793 · es1701017_4-pelossof.xml · derivative · entry 14

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,470 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, at the Effective Time, each outstanding Restricted Stock Unit was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration.

F3 · price: Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, at the Effective Time, each outstanding Restricted Stock Unit was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration.

F3 · derivative.exercise_date: Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, at the Effective Time, each outstanding Restricted Stock Unit was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration.

F3 · derivative.expiration_date: Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, at the Effective Time, each outstanding Restricted Stock Unit was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time and (ii) the Merger Consideration.

SEC source: 0000950142-17-001793 · es1701017_4-pelossof.xml · derivative · entry 13

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

SEC source: 0000950142-17-001793 · es1701017_4-pelossof.xml · derivative · entry 12

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,250 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

SEC source: 0000950142-17-001793 · es1701017_4-pelossof.xml · derivative · entry 11

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,125 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

SEC source: 0000950142-17-001793 · es1701017_4-pelossof.xml · derivative · entry 10

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

SEC source: 0000950142-17-001793 · es1701017_4-pelossof.xml · derivative · entry 9

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 45,000 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

SEC source: 0000950142-17-001793 · es1701017_4-pelossof.xml · derivative · entry 8

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

SEC source: 0000950142-17-001793 · es1701017_4-pelossof.xml · derivative · entry 7

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

SEC source: 0000950142-17-001793 · es1701017_4-pelossof.xml · derivative · entry 6

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

SEC source: 0000950142-17-001793 · es1701017_4-pelossof.xml · derivative · entry 5

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

SEC source: 0000950142-17-001793 · es1701017_4-pelossof.xml · derivative · entry 4

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 14,081 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

SEC source: 0000950142-17-001793 · es1701017_4-pelossof.xml · derivative · entry 3

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,500 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

SEC source: 0000950142-17-001793 · es1701017_4-pelossof.xml · derivative · entry 2

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires not disclosed

F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

F2 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding Employee Stock Option, whether vested or unvested, was canceled and converted into the right to receive a lump-sum cash payment equal to the product of (i) the number of shares of Common Stock for which such Employee Stock Option has not been exercised and (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Employee Stock Option.

SEC source: 0000950142-17-001793 · es1701017_4-pelossof.xml · nonDerivative · entry 1

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: Pursuant to that certain Agreement and Plan of Merger, dated as of January 30, 2016, as amended on April 13, 2017 (the "Merger Agreement"), between Alere Inc. (the "Company") and Abbott Laboratories, at the Effective Time (as defined in the Merger Agreement) (the "Effective Time"), each of these shares of the Company's common stock (the "Common Stock") was converted into the right to receive $51.00 (the "Merger Consideration").

SEC source: 0001179110-17-012026 · edgar.xml · derivative · entry 3

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock.

F2 · derivative.exercise_date: The restricted stock units were awarded pursuant to a restricted stock unit agreement on August 31, 2014 and will vest as follows: 6,666 on the first anniversary of the grant date (8/31/15); 6,667 on the second anniversary of the grant date (8/31/16); and 6,667 on the third anniversary of the grant date (8/31/17).

F2 · derivative.expiration_date: The restricted stock units were awarded pursuant to a restricted stock unit agreement on August 31, 2014 and will vest as follows: 6,666 on the first anniversary of the grant date (8/31/15); 6,667 on the second anniversary of the grant date (8/31/16); and 6,667 on the third anniversary of the grant date (8/31/17).

SEC source: 0001179110-17-012026 · edgar.xml · nonDerivative · entry 2

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,005

SEC source: 0001179110-17-012026 · edgar.xml · nonDerivative · entry 1

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,469

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock.

SEC source: 0001179110-17-002832 · edgar.xml · derivative · entry 6

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,470

Underlying: Common Stock · 7,236 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock.

F3 · derivative.exercise_date: On February 16, 2016 the reporting person was granted 21,706 restricted stock units which vest as follows: one-third on the first anniversary of the grant date (2/16/17); one-third on the second anniversary of the grant date (2/16/18); and one-third on the third anniversary of the grant date (2/16/19).

F3 · derivative.expiration_date: On February 16, 2016 the reporting person was granted 21,706 restricted stock units which vest as follows: one-third on the first anniversary of the grant date (2/16/17); one-third on the second anniversary of the grant date (2/16/18); and one-third on the third anniversary of the grant date (2/16/19).

SEC source: 0001179110-17-002832 · edgar.xml · derivative · entry 5

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 2,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock.

F2 · derivative.exercise_date: On February 16, 2016 the reporting person was granted 7,500 restricted stock units which vest as follows: one-third on the first anniversary of the grant date (2/16/17); one-third on the second anniversary of the grant date (2/16/18); and one-third on the third anniversary of the grant date (2/16/19).

F2 · derivative.expiration_date: On February 16, 2016 the reporting person was granted 7,500 restricted stock units which vest as follows: one-third on the first anniversary of the grant date (2/16/17); one-third on the second anniversary of the grant date (2/16/18); and one-third on the third anniversary of the grant date (2/16/19).

SEC source: 0001179110-17-002832 · edgar.xml · nonDerivative · entry 4

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,802

SEC source: 0001179110-17-002832 · edgar.xml · nonDerivative · entry 3

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,543

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock.

SEC source: 0001179110-17-002832 · edgar.xml · nonDerivative · entry 2

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,307

SEC source: 0001179110-17-002832 · edgar.xml · nonDerivative · entry 1

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,231

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock.

SEC source: 0001179110-17-000380 · edgar.xml · derivative · entry 9

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,332 shares

Expires 2017-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: This derivative security does not have a price.

F1 · derivative.exercise_date: These options became exercisable in four equal annual installments beginning January 1, 2007.

F4 · derivative.expiration_date: The Options were scheduled to expire on January 1, 2017.

SEC source: 0001179110-17-000380 · edgar.xml · derivative · entry 8

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,668 shares

Expires 2017-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: This derivative security does not have a price.

F1 · derivative.exercise_date: These options became exercisable in four equal annual installments beginning January 1, 2007.

F4 · derivative.expiration_date: The Options were scheduled to expire on January 1, 2017.

SEC source: 0001179110-17-000380 · edgar.xml · derivative · entry 7

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,668

Underlying: Common Stock · 20,000 shares

Expires 2017-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: This derivative security does not have a price.

F1 · derivative.exercise_date: These options became exercisable in four equal annual installments beginning January 1, 2007.

F4 · derivative.expiration_date: The Options were scheduled to expire on January 1, 2017.

SEC source: 0001179110-17-000380 · edgar.xml · nonDerivative · entry 6

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,731

F3 · shares: Represents withholding of shares of Company common stock to satisfy exercise price and tax liability associated with exercise of stock options shown above.

SEC source: 0001179110-17-000380 · edgar.xml · nonDerivative · entry 5

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,994

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-17-000380 · edgar.xml · nonDerivative · entry 4

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,662

F3 · shares: Represents withholding of shares of Company common stock to satisfy exercise price and tax liability associated with exercise of stock options shown above.

SEC source: 0001179110-17-000380 · edgar.xml · nonDerivative · entry 3

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,289

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-17-000380 · edgar.xml · nonDerivative · entry 2

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,621

F3 · shares: Represents withholding of shares of Company common stock to satisfy exercise price and tax liability associated with exercise of stock options shown above.

SEC source: 0001179110-17-000380 · edgar.xml · nonDerivative · entry 1

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,524

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001179110-16-029624 · edgar.xml · derivative · entry 2

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,667

Underlying: Common Stock · 6,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock.

F2 · derivative.exercise_date: The restricted stock units were awarded pursuant to a restricted stock unit agreement on August 31, 2014 and will vest as follows: 6,666 on the first anniversary of the grant date (8/31/15); 6,667 on the second anniversary of the grant date (8/31/16); and 6,667 on the third anniversary of the grant date (8/31/17).

F2 · derivative.expiration_date: The restricted stock units were awarded pursuant to a restricted stock unit agreement on August 31, 2014 and will vest as follows: 6,666 on the first anniversary of the grant date (8/31/15); 6,667 on the second anniversary of the grant date (8/31/16); and 6,667 on the third anniversary of the grant date (8/31/17).

SEC source: 0001179110-16-029624 · edgar.xml · nonDerivative · entry 1

Pelossof Avi · CIK 0001293460 · GlobalPres, Infectious Disease

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,524

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · date: Vesting of shares under the Alere 2010 Stock Option and Incentive Plan was suspended from March 1, 2016 until two business days after Alere's SEC filings became current. Shares vested on September 9, 2016 represent shares that otherwise would have vested during the suspension period.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of Alere common stock.